GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » Debt-to-EBITDA

Cereno Scientific AB (OSTO:CRNO B) Debt-to-EBITDA : -2.60 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cereno Scientific AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr0.00 Mil. Cereno Scientific AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was kr180.40 Mil. Cereno Scientific AB's annualized EBITDA for the quarter that ended in Mar. 2025 was kr-69.36 Mil. Cereno Scientific AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was -2.60.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Cereno Scientific AB's Debt-to-EBITDA or its related term are showing as below:

OSTO:CRNO B' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.6   Med: -0.38   Max: -0.02
Current: -2.35

During the past 10 years, the highest Debt-to-EBITDA Ratio of Cereno Scientific AB was -0.02. The lowest was -2.60. And the median was -0.38.

OSTO:CRNO B's Debt-to-EBITDA is ranked worse than
100% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.71 vs OSTO:CRNO B: -2.35

Cereno Scientific AB Debt-to-EBITDA Historical Data

The historical data trend for Cereno Scientific AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB Debt-to-EBITDA Chart

Cereno Scientific AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.35 -0.02 -1.06 -2.60

Cereno Scientific AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.82 -0.58 -1.49 -1.93 -2.60

Competitive Comparison of Cereno Scientific AB's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's Debt-to-EBITDA falls into.


;
;

Cereno Scientific AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Cereno Scientific AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 190.4) / -73.152
=-2.60

Cereno Scientific AB's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 180.4) / -69.36
=-2.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.


Cereno Scientific AB  (OSTO:CRNO B) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Cereno Scientific AB Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Cereno Scientific AB's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Cereno Scientific AB Business Description

Traded in Other Exchanges
Address
BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines